Working... Menu

Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02475629
Recruitment Status : Completed
First Posted : June 19, 2015
Last Update Posted : February 8, 2017
Information provided by (Responsible Party):
TaiMed Biologics Inc.

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : October 2016
  Actual Study Completion Date : December 2016